<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/285o–4" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/285o–4/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/285o–4/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_285o_4"><akn:num>285o–4</akn:num><akn:heading>Medication Development Program</akn:heading><akn:content><akn:p>§ 285o–4. Medication Development Program(a) EstablishmentThere is established in the Institute a Medication Development Program through which the Director of such Institute shall—(1) conduct periodic meetings with the Commissioner of Food and Drugs to discuss measures that may facilitate the approval process of drug abuse treatments;

(2) encourage and promote (through grants, contracts, international collaboration, or otherwise) expanded research programs, investigations, experiments, community trials, and studies, into the development and use of medications to treat drug addiction;

(3) establish or provide for the establishment of research facilities;

(4) report on the activities of other relevant agencies relating to the development and use of pharmacotherapeutic treatments for drug addiction;

(5) collect, analyze, and disseminate data useful in the development and use of pharmacotherapeutic treatments for drug addiction and collect, catalog, analyze, and disseminate through international channels, the results of such research;

(6) directly or through grants, contracts, or cooperative agreements, support training in the fundamental sciences and clinical disciplines related to the pharmacotherapeutic treatment of drug abuse, including the use of training stipends, fellowships, and awards where appropriate; and

(7) coordinate the activities conducted under this section with related activities conducted within the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Mental Health, and other appropriate institutes and shall consult with the Directors of such Institutes.


(b) DutiesIn carrying out the activities described in subsection (a), the Director of the Institute—(1) shall collect and disseminate through publications and other appropriate means, information pertaining to the research and other activities under this section;

(2) shall make grants to or enter into contracts and cooperative agreements with individuals and public and</akn:p></akn:content><akn:subsection eId="subsec_285o_4_a"><akn:num>(a)</akn:num><akn:heading>Establishment</akn:heading><akn:content><akn:p>(a) Establishment There is established in the Institute a Medication Development Program through which the Director of such Institute shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285o_4_b"><akn:num>(b)</akn:num><akn:heading>Duties</akn:heading><akn:content><akn:p>(b) Duties In carrying out the activities described in subsection (a), the Director of the Institute—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285o_4_c"><akn:num>(c)</akn:num><akn:heading>Report</akn:heading><akn:content><akn:p>(c) Report</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285o_4_d"><akn:num>(d)</akn:num><akn:heading>“Pharmacotherapeutics” defined</akn:heading><akn:content><akn:p>(d) “Pharmacotherapeutics” defined For purposes of this section, the term “pharmacotherapeutics” means medications used to treat the symptoms and disease of drug abuse, including medications to—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>